Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation
Version 2 2024-06-06, 07:11
Version 1 2021-03-26, 08:25
journal contribution
posted on 2024-06-06, 07:11 authored by RS McIntyre, JD Rosenblat, CB Nemeroff, G Sanacora, JW Murrough, Michael BerkMichael Berk, E Brietzke, Seetal DoddSeetal Dodd, P Gorwood, R Ho, DV Iosifescu, CL Jaramillo, S Kasper, K Kratiuk, JG Lee, Y Lee, LMW Lui, RB Mansur, GI Papakostas, M Subramaniapillai, M Thase, E Vieta, AH Young, CA Zarate, S StahlSynthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation
History
Journal
American Journal of PsychiatryVolume
178Pagination
383-399Location
Washington, D.C.Publisher DOI
ISSN
0002-953XeISSN
1535-7228Language
EnglishPublication classification
C1 Refereed article in a scholarly journalIssue
5Publisher
AMER PSYCHIATRIC PUBLISHINGUsage metrics
Categories
No categories selectedKeywords
ANTIDEPRESSANTDOSE INTRAVENOUS KETAMINEDOUBLE-BLINDEFFICACYINTRANASALLife Sciences & BiomedicineMAJOR DEPRESSIONMOOD DISORDERSNASAL SPRAYPsychiatryScience & TechnologySUICIDAL IDEATIONSYMPTOMS110999 Neurosciences not elsewhere classified920410 Mental HealthSchool of MedicineFaculty of HealthInstitute for Innovation in Mental and Physical Health and Clinical Translation3209 Neurosciences3202 Clinical sciences3214 Pharmacology and pharmaceutical sciences420313 Mental health services200409 Mental health
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC